Trends in Alzheimer Disease Therapy Analyzed in New Topical FirstWord Report
21 Nov 2012 • by Natalie Aster
The release of Phase III trials for disease modifying therapies has made 2012 a crucial year for Alzheimer's disease. Disappointing trial results for Pfizer and Johnson & Johnson's bapineuzumab have highlighted the difficulties in Alzheimer drug development and have further dimmed prospects for other pipeline drugs.
“Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules” report by FirstWord comes in two modules.
Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules
Published: August, 2012
Price: US$ 7.495,00
KOL Insight provides concise, qualitative KOL analysis of the current and predicted treatment trends, clinical products, and commercial changes in the global sector provided by 8-12 of the field’s foremost key opinion leaders.
Consensus Outlook provides an in-depth 5-year report of the predicted quantitative changes in key market forecast parameters. This module offers access to various charts including market size, product sales, market share by company, competitive status, and detailed market forecasts.
More information can be found in the report “Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules” by FirstWord.
To order the report or ask for sample pages contact [email protected]ublishers.com